Share on StockTwits

Analysts at Stifel Nicolaus upped their price target on shares of Auspex Pharmaceuticals (NASDAQ:ASPX) from $39.00 to $40.00 in a report issued on Friday. The firm currently has a “buy” rating on the stock. Stifel Nicolaus’ price objective would suggest a potential upside of 105.13% from the stock’s previous close.

Separately, analysts at Robert W. Baird raised their price target on shares of Auspex Pharmaceuticals from $34.00 to $42.00 in a research note on Friday, July 11th. They now have an “outperform” rating on the stock.

Auspex Pharmaceuticals (NASDAQ:ASPX) opened at 19.50 on Friday. Auspex Pharmaceuticals has a 52-week low of $13.25 and a 52-week high of $35.78. The stock’s 50-day moving average is $20.63 and its 200-day moving average is $23.00. The company’s market cap is $445.6 million.

Auspex Pharmaceuticals (NASDAQ:ASPX) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.45) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.33) by $0.12. Analysts expect that Auspex Pharmaceuticals will post $-1.93 EPS for the current fiscal year.

Auspex Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of medicines for the treatment of orphan diseases.

Receive News & Ratings for Auspex Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auspex Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.